Tirzepatide pom zoo rau Kev Tswj Xyuas Qhov hnyav hauv Suav teb

Tirzepatide Pom zoo rau Kev Tswj Xyuas Qhov hnyav hauv Suav teb

 

Thaum Lub Xya Hli 19, 2024, National Medical Products Administration (NMPA) ntawm Tuam Tshoj tau pom zoo ib qho kev qhia tshiab rau Eli Lilly's tirzepatide txhaj rau kev tswj qhov hnyav mus ntev. Qhov no ua raws li kev pom zoo ntawm nws cov lus qhia rau kev tswj ntshav qab zib, ua rau nws yog qhov qhia thib ob rau tirzepatide hauv Suav teb. Tirzepatide yog glucagon-zoo li peptide-1 (GLP-1) thiab gastric inhibitory polypeptide (GIP) receptor agonist uas ua haujlwm los ntawm kev tswj kev qab los noj mov kom tsis txhob noj zaub mov, txo lub cev hnyav, thiab txo cov rog rog.

Kev tswj hwm qhov hnyav rau tirzepatide yog tsim rau cov neeg laus uas muaj lub cev qhov hnyav (BMI) ntawm 28 kg / m² lossis ntau dua (kev rog), lossis BMI ntawm 24 kg / m² lossis ntau dua (hnyav) nrog tsawg kawg ib qho hnyav hnyav. , xws li kub siab, dyslipidemia, hyperglycemia, obstructive pw tsaug zog apnea, kab mob plawv, thiab lwm yam. Qhov kev pom zoo no muab kev kho mob tshiab. kev xaiv rau cov neeg mob rog rog thiab rog dhau.

Tsis tas li ntawd, qhov hnyav poob ntawm tirzepatide yog qhov tseem ceeb. Raws li SURMOUNT-CN Phase III kev soj ntsuam cov txiaj ntsig, ntawm lub lim tiam 52, cov neeg laus rog rog thiab rog rog suav nrog tirzepatide tau txo qhov hnyav tshaj li 19.9% ​​piv rau cov hauv paus.

GenoHope Biotech Co., Ltd.
Ib lub tuam txhab ua lag luam ntawm GLP-1 API
Pom zoo los ntawm FDA
Zoo siab txais tos txhua qhov kev nug
WhatsApp / Tel: +8613833133635
Email:info@genohopebio.com